Recombinant human acid ??-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trial-Reference-Cited by-同舟云学术

Recombinant human acid ??-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trial

Published:2001-03 Issue:2 Volume:3 Page:132-138
ISSN:1098-3600
Container-title:Genetics in Medicine
language:en
Short-container-title:Genetics in Medicine

Author:

Amalfitano Andrea,Bengur A. Resai,Morse Richard P.,Majure Joseph M.,Case Laura E.,Veerling Deborah L.,Mackey Joanne,Kishnani Priya,Smith Wendy,McVie-Wylie Alison,Sullivan Jennifer A.,Hoganson George E.,Phillips John A.,Schaefer G. Bradley,Charrow Joel,Ware Russell E.,Bossen Edward H.,Chen Yuan-Tsong

Publisher

Elsevier BV

Subject

Genetics(clinical)

Reference18 articles.

1. Identification of two subtypes of infantile acid maltase deficiency

2. Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease

3. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling

4. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease.

Cited by 308 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acid α-glucosidase (GAA) activity and glycogen content in muscle biopsy specimens of patients with Pompe disease: A systematic review;Molecular Genetics and Metabolism Reports;2024-06

2. Clinical pharmacology considerations for first‐in‐human clinical trials for enzyme replacement therapy;Journal of Inherited Metabolic Disease;2024-05-13

3. Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers;Frontiers in Oncology;2024-04-19

4. An updated management approach of Pompe disease patients with high-sustained anti-rhGAA IgG antibody titers: experience with bortezomib-based immunomodulation;Frontiers in Immunology;2024-03-08

5. The Importance of Early Treatment of Inherited Neuromuscular Conditions;Journal of Neuromuscular Diseases;2024-03-05